Abstract |
A new double-strength (84 micrograms/spray) formulation of beclomethasone dipropionate (BDP-ds) as an aqueous suspension has been introduced to control symptoms of allergic rhinitis with once-daily intranasal dosing. This paper reviews the results of three clinical reports which show that BDP-ds given once a day is more effective than placebo and as effective as regular-strength beclomethasone dipropionate given twice daily in reducing the nasal symptoms of seasonal allergic rhinitis. Symptom improvement was seen within 2 days of treatment initiation and was maintained for the subsequent 4 weeks. BDP-ds was found to be as safe and well tolerated as placebo. Adverse effects, which were generally mild, included headache, nasal burning/irritation, epistaxis, coughing, and pharyngitis. BDP-ds is safe for children as young as 6 years of age, and its once-daily dosing schedule may improve patient compliance.
|
Authors | P Chervinsky |
Journal | Clinical therapeutics
(Clin Ther)
1996 Sep-Oct
Vol. 18
Issue 5
Pg. 790-6; discussion 789
ISSN: 0149-2918 [Print] United States |
PMID | 8930423
(Publication Type: Journal Article, Review)
|
Chemical References |
- Glucocorticoids
- Beclomethasone
|
Topics |
- Administration, Intranasal
- Adult
- Beclomethasone
(administration & dosage, therapeutic use)
- Child
- Drug Tolerance
- Glucocorticoids
(administration & dosage, therapeutic use)
- Humans
- Rhinitis, Allergic, Seasonal
(drug therapy)
|